Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Tax Provisions (2020 - 2022)

Tarsus Pharmaceuticals has reported Tax Provisions over the past 3 years, most recently at -$5000.0 for Q3 2022.

  • Quarterly results put Tax Provisions at -$5000.0 for Q3 2022, up 98.53% from a year ago — trailing twelve months through Jun 2023 was -$5000.0 (up 98.25% YoY), and the annual figure for FY2025 was $2.1 million, changed.
  • Tax Provisions for Q3 2022 was -$5000.0 at Tarsus Pharmaceuticals, down from $1000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for TARS hit a ceiling of $313000.0 in Q1 2021 and a floor of -$341000.0 in Q3 2021.
  • Median Tax Provisions over the past 3 years was $1000.0 (2020), compared with a mean of $7428.6.
  • Biggest five-year swings in Tax Provisions: crashed 34200.0% in 2021 and later skyrocketed 98.53% in 2022.
  • Tarsus Pharmaceuticals' Tax Provisions stood at $1000.0 in 2020, then soared by 5300.0% to $54000.0 in 2021, then crashed by 109.26% to -$5000.0 in 2022.
  • The last three reported values for Tax Provisions were -$5000.0 (Q3 2022), $1000.0 (Q1 2022), and $54000.0 (Q4 2021) per Business Quant data.